Acute Myeloid Leukemia Clinical Trials

None

None

UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.

UPCC 17418: A Phase 2b Open-Label Single Arm Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Standard Induction Therapy

The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.

UPCC 11417: A Phase 3 Multicenter Randomized Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Request for collaborative review: WIRB serving as IRB of record.

UPCC 14419: A Phase 1 First in Human Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.

UPCC 44419: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …

UPCC 13418: A Multicenter Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.

UPCC 03418: A Phase 1 First in Human Open Label Dose Escalation Study of AMV564 a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia

(Amphivena) is studying an investigational drug called AMV564, which may help to treat acute myeloid leukemia (AML). The purpose of this clinical research study is to find the highest tolerable dose that can be given to patients with AML, and to recommend a dose to be used in future studies.

UPCC#01409: Lintuzumab-Ac225 in Older Patients with Untreated AML

This is a phase 1/2 study of a radio-labeled investigational drug, 225Ac-lintuzumab, given in combination with low-dose cytarabine in previously untreated elderly patients with AML. Phase 1 will establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside, and Phase 2 will help determine the …